中华普通外科杂志
中華普通外科雜誌
중화보통외과잡지
Chinese Journal of General Surgery
2015年
9期
726-729
,共4页
颜艺超%申占龙%姜可伟%叶颖江%王杉
顏藝超%申佔龍%薑可偉%葉穎江%王杉
안예초%신점룡%강가위%협영강%왕삼
胃肿瘤%次要组织相容性抗原%血红素氧化酶(脱环)%肿瘤转移%预后
胃腫瘤%次要組織相容性抗原%血紅素氧化酶(脫環)%腫瘤轉移%預後
위종류%차요조직상용성항원%혈홍소양화매(탈배)%종류전이%예후
Stomach neoplasms%Minor histocompatibility antigens%Heme oxygenase (Decyclizing)%Neoplasm metastasis%Prognosis
目的 探讨次要组织相容性抗原13(minor histocompatibility antigen 13,HM13)蛋白在胃癌组织中的表达情况及其与患者临床病理指标和预后的关系.方法 应用免疫组化法检测90例胃癌及癌旁组织中HM13蛋白的表达,并分析其与胃癌患者临床病理指标及预后的相关性;qRT-PCR检测HM13干扰后下游基因血红素氧化酶1的表达改变.结果 胃癌组织中HM13的表达比癌旁正常组织中的表达降低,二者的高表达率分别为47％和61％,但差异无统计学意义(x2=3.78,P=0.052).HM13蛋白表达与胃癌TNM分期(x2=5.022,P=0.025)及远处转移(P =0.033)有关,而与患者年龄(x2=0.832,P=0.362)、性别(x2=0.779,P=0.378)、肿瘤大小(x2=0.804,P=0.370)、分化程度(x2 =0.430,P=0.512)、大体类型(x2=2.069,P=0.150)、浸润深度(x2=0.167,P=0.683)及有无淋巴转移(x2 =0.396,P=0.529)无关.HM13蛋白低表达的胃癌患者比高表达胃癌患者的预后差(中位总生存期:15个月比54个月,x2=6.456,P=0.011;中位无进展生存期:13个月比48个月,x2=6.742,P=0.009).干扰HM13表达后血红素氧化酶1表达上调(0.532±0.013比0.395±0.011,t=13.93,P＜0.05).结论 HM13低表达与肿瘤的进展、转移及不良预后密切相关.
目的 探討次要組織相容性抗原13(minor histocompatibility antigen 13,HM13)蛋白在胃癌組織中的錶達情況及其與患者臨床病理指標和預後的關繫.方法 應用免疫組化法檢測90例胃癌及癌徬組織中HM13蛋白的錶達,併分析其與胃癌患者臨床病理指標及預後的相關性;qRT-PCR檢測HM13榦擾後下遊基因血紅素氧化酶1的錶達改變.結果 胃癌組織中HM13的錶達比癌徬正常組織中的錶達降低,二者的高錶達率分彆為47％和61％,但差異無統計學意義(x2=3.78,P=0.052).HM13蛋白錶達與胃癌TNM分期(x2=5.022,P=0.025)及遠處轉移(P =0.033)有關,而與患者年齡(x2=0.832,P=0.362)、性彆(x2=0.779,P=0.378)、腫瘤大小(x2=0.804,P=0.370)、分化程度(x2 =0.430,P=0.512)、大體類型(x2=2.069,P=0.150)、浸潤深度(x2=0.167,P=0.683)及有無淋巴轉移(x2 =0.396,P=0.529)無關.HM13蛋白低錶達的胃癌患者比高錶達胃癌患者的預後差(中位總生存期:15箇月比54箇月,x2=6.456,P=0.011;中位無進展生存期:13箇月比48箇月,x2=6.742,P=0.009).榦擾HM13錶達後血紅素氧化酶1錶達上調(0.532±0.013比0.395±0.011,t=13.93,P＜0.05).結論 HM13低錶達與腫瘤的進展、轉移及不良預後密切相關.
목적 탐토차요조직상용성항원13(minor histocompatibility antigen 13,HM13)단백재위암조직중적표체정황급기여환자림상병리지표화예후적관계.방법 응용면역조화법검측90례위암급암방조직중HM13단백적표체,병분석기여위암환자림상병리지표급예후적상관성;qRT-PCR검측HM13간우후하유기인혈홍소양화매1적표체개변.결과 위암조직중HM13적표체비암방정상조직중적표체강저,이자적고표체솔분별위47％화61％,단차이무통계학의의(x2=3.78,P=0.052).HM13단백표체여위암TNM분기(x2=5.022,P=0.025)급원처전이(P =0.033)유관,이여환자년령(x2=0.832,P=0.362)、성별(x2=0.779,P=0.378)、종류대소(x2=0.804,P=0.370)、분화정도(x2 =0.430,P=0.512)、대체류형(x2=2.069,P=0.150)、침윤심도(x2=0.167,P=0.683)급유무림파전이(x2 =0.396,P=0.529)무관.HM13단백저표체적위암환자비고표체위암환자적예후차(중위총생존기:15개월비54개월,x2=6.456,P=0.011;중위무진전생존기:13개월비48개월,x2=6.742,P=0.009).간우HM13표체후혈홍소양화매1표체상조(0.532±0.013비0.395±0.011,t=13.93,P＜0.05).결론 HM13저표체여종류적진전、전이급불량예후밀절상관.
Objective To explore the expression of ininor histocompatibility antigen 13 (HM1 3) in gastric carcinoma and the relationship with clinicopathological parameters and prognosis.Methods The expression of HM 13 was detected by immunohistochemistry in a total of 90 pairs of paraffin-embedded gastric cancer tissue specimens and corresponding paraneoplastic tissues.The correlation between clinicopathological parameters and the expression of HM13 in gastric carcinoma were also analyzed.Downstream gene heme oxygenase-1 (HO-1) expression was detected by qRT-PCR after HM13 gene was interfered.Results High expression of HM13 protein was observed in 47％ gastric carcinoma compared with that in 61％ corresponding paraneoplastic tissues (x2 =3.78,P =0.052).HM13 expression has positive correlation with pathological TNM stage (x2 =5.022,P =0.025) and distant metastasis (P =0.033),but not with age (x2 =0.832,P =0.362),gender (x2 =0.779,P =0.378),tumor size (x2 =0.804,P =0.370),tumor differentiation (x2 =0.430,P =0.512),gross types (x2 =2.069,P =0.150),tumor stromal invasion (x2 =0.167,P =0.683) and lymph node status (x2 =0.396,P =0.529).The patients with low HM13 expression had worse overall survival [(OS):(30 ± 5) months vs.(47 ± 5) months,x2 =6.456,P =0.011] and progress free survival [(PFS):(29 ± 5) months vs.(46 ± 5) months,x2 =6.742,P =0.009].Expression of HO-1 was up-regulated after HM13 gene was interfered (0.532±0.013 vs.0.395±0.011,t=13.93,P＜0.05).Conclusion The low expression of HM13 is associated closely with advanced stage and distant metastases of gastric carcinoma.
